ATE535535T1 - Methoden für die diagnose von demenz und anderen neurologischen erkrankungen - Google Patents
Methoden für die diagnose von demenz und anderen neurologischen erkrankungenInfo
- Publication number
- ATE535535T1 ATE535535T1 AT07710657T AT07710657T ATE535535T1 AT E535535 T1 ATE535535 T1 AT E535535T1 AT 07710657 T AT07710657 T AT 07710657T AT 07710657 T AT07710657 T AT 07710657T AT E535535 T1 ATE535535 T1 AT E535535T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- alzheimer
- disease dementia
- accurate mass
- methods
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004896 high resolution mass spectrometry Methods 0.000 abstract 1
- 239000013074 reference sample Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N37/00—Details not covered by any other group of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Primary Health Care (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77729006P | 2006-02-28 | 2006-02-28 | |
| US80477906P | 2006-06-14 | 2006-06-14 | |
| US88888307P | 2007-02-08 | 2007-02-08 | |
| PCT/CA2007/000313 WO2007098585A1 (en) | 2006-02-28 | 2007-02-28 | Methods for the diagnosis of dementia and other neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535535T1 true ATE535535T1 (de) | 2011-12-15 |
Family
ID=38458611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07710657T ATE535535T1 (de) | 2006-02-28 | 2007-02-28 | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8304246B2 (de) |
| EP (3) | EP2851369A3 (de) |
| JP (3) | JP5496513B2 (de) |
| KR (1) | KR20080104350A (de) |
| AT (1) | ATE535535T1 (de) |
| AU (1) | AU2007219666A1 (de) |
| CA (2) | CA2689848A1 (de) |
| HK (1) | HK1208467A1 (de) |
| IL (1) | IL193426A0 (de) |
| NZ (1) | NZ570413A (de) |
| WO (1) | WO2007098585A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095275A1 (en) | 2007-02-08 | 2008-08-14 | Phenomenome Discoveries Inc. | Methods for the treatment of senile dementia of the alzheimer's type |
| US20100105101A1 (en) | 2007-04-13 | 2010-04-29 | Phenomenome Discoveries Inc. | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging |
| SG182971A1 (en) * | 2007-07-26 | 2012-08-30 | Phenomenome Discoveries Inc | Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders |
| KR20180090396A (ko) | 2008-01-18 | 2018-08-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
| US9965035B2 (en) | 2008-05-13 | 2018-05-08 | Apple Inc. | Device, method, and graphical user interface for synchronizing two or more displays |
| US9121844B1 (en) * | 2008-09-09 | 2015-09-01 | Sociedad Europea de Analisis Diferencial de Movilidad | Method to analyze and classify persons and organisms based on odor patterns from released vapors |
| TWI475989B (zh) | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法 |
| EP2770328B1 (de) | 2009-10-01 | 2017-12-27 | Phenomenome Discoveries Inc. | Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs |
| AU2011280944A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| AU2011280936A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| MX382244B (es) | 2010-07-23 | 2025-03-13 | Harvard College | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales |
| WO2012090625A1 (ja) * | 2010-12-28 | 2012-07-05 | 医療法人社団ブックス | 認知症を血液サンプルで判定するための検査方法 |
| AU2012321071B2 (en) * | 2011-11-17 | 2015-02-26 | Med-Life Discoveries Lp | Methods for the synthesis of 13C labeled plasmalogen |
| WO2013119651A1 (en) * | 2012-02-08 | 2013-08-15 | Nestec Sa | Methods for diagnosing cognitive impairment |
| US20150031572A1 (en) * | 2012-02-15 | 2015-01-29 | Basf Se | Means and methods for assessing neuronal toxicity |
| EP2831782A2 (de) * | 2012-03-29 | 2015-02-04 | Koninklijke Philips N.V. | System und verfahren zur verbesserung des behandlungsworkflows von morbus alzheimer durch neurologen |
| US20140179805A1 (en) | 2012-06-15 | 2014-06-26 | Harry Stylli | Methods of detecting diseases or conditions |
| SG11201408383SA (en) | 2012-06-15 | 2015-01-29 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| EP2965086A4 (de) | 2013-03-09 | 2017-02-08 | Harry Stylli | Verfahren zum nachweis von prostatakrebs |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| WO2014197339A1 (en) * | 2013-06-08 | 2014-12-11 | Apple Inc. | Device, method, and graphical user interface for synchronizing two or more displays |
| JP6495902B2 (ja) * | 2013-11-14 | 2019-04-03 | ネステク ソシエテ アノニム | 健康的な加齢に関係する脂質バイオマーカー |
| WO2015138879A1 (en) * | 2014-03-13 | 2015-09-17 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
| US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
| GB201611596D0 (en) * | 2016-07-04 | 2016-08-17 | British American Tobacco Investments Ltd | Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories |
| US20200241011A1 (en) * | 2017-02-24 | 2020-07-30 | Mattias ARNOLD | Compositions and methods related to sex- specific metabolic drivers in alzheimers disease |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US20190385711A1 (en) | 2018-06-19 | 2019-12-19 | Ellipsis Health, Inc. | Systems and methods for mental health assessment |
| JP7608171B2 (ja) | 2018-06-19 | 2025-01-06 | エリプシス・ヘルス・インコーポレイテッド | 精神的健康評価のためのシステム及び方法 |
| US12029579B2 (en) * | 2018-07-13 | 2024-07-09 | Pst Inc. | Apparatus for estimating mental/neurological disease |
| EP3849410A4 (de) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | System und verfahren zur verbesserung des schlafs |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2022263927A2 (en) * | 2021-06-17 | 2022-12-22 | Phoska Biopharma Pte. Ltd. | Plasmalogen derivatives and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| US5731354A (en) | 1996-05-06 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Treatment for the inhibition of neuro-degenerative disease states |
| US6177476B1 (en) | 1998-08-27 | 2001-01-23 | Clarion Pharmaceuticals Inc. | Nutritional supplements for replenishing plasmalogens |
| CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
| EP2330219A3 (de) | 2000-04-14 | 2011-11-23 | Metabolon, Inc. | Verfahren zur Arzneimittelentdeckung, Krankheitsbehandlung und Diagnose mithilfe eines Metaboloms |
| AU2001286059A1 (en) | 2000-09-08 | 2002-03-22 | Oxford Glycosciences (Uk) Ltd. | Automated identification of peptides |
| DE10291524D2 (de) * | 2001-04-06 | 2004-07-01 | Anker Thorsten | Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien |
| AU2002341488A1 (en) * | 2001-05-09 | 2002-11-18 | Biovision Ag | Method for detecting progredient chronic dementia, and associated peptides and detection reagents |
| EP2221620B1 (de) * | 2002-08-23 | 2013-10-02 | Bayer Pharma Aktiengesellschaft | Biomarker zur Diagnose von Alzheimer |
| EP1694816B1 (de) * | 2003-11-07 | 2013-08-28 | Ciphergen Biosystems, Inc. | Biomarker für morbus alzheimer |
| WO2005085838A2 (en) * | 2004-03-02 | 2005-09-15 | Vanderbilt University | Computational analysis of mass spectroscopic lipid data |
| WO2005116659A2 (en) * | 2004-05-18 | 2005-12-08 | Neurodx, Llc | Compositions and methods relating to alzheimer’s disease |
| JP4176749B2 (ja) * | 2005-07-29 | 2008-11-05 | 学校法人帝京大学 | 疾病検査法 |
| US8026099B2 (en) * | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
-
2007
- 2007-02-28 US US12/280,920 patent/US8304246B2/en active Active
- 2007-02-28 NZ NZ570413A patent/NZ570413A/en unknown
- 2007-02-28 EP EP14187832.2A patent/EP2851369A3/de not_active Withdrawn
- 2007-02-28 KR KR1020087023687A patent/KR20080104350A/ko not_active Withdrawn
- 2007-02-28 EP EP10195818A patent/EP2322531A3/de not_active Ceased
- 2007-02-28 CA CA2689848A patent/CA2689848A1/en not_active Abandoned
- 2007-02-28 EP EP07710657A patent/EP1922325B1/de active Active
- 2007-02-28 WO PCT/CA2007/000313 patent/WO2007098585A1/en not_active Ceased
- 2007-02-28 CA CA2640748A patent/CA2640748C/en active Active
- 2007-02-28 AU AU2007219666A patent/AU2007219666A1/en not_active Abandoned
- 2007-02-28 AT AT07710657T patent/ATE535535T1/de active
- 2007-02-28 JP JP2008556622A patent/JP5496513B2/ja active Active
-
2008
- 2008-08-08 HK HK15109254.5A patent/HK1208467A1/en unknown
- 2008-08-13 IL IL193426A patent/IL193426A0/en unknown
-
2012
- 2012-07-31 JP JP2012169181A patent/JP2012255793A/ja active Pending
- 2012-09-25 US US13/626,703 patent/US20130110408A1/en not_active Abandoned
-
2014
- 2014-06-26 JP JP2014131876A patent/JP2014197018A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009528517A (ja) | 2009-08-06 |
| EP1922325B1 (de) | 2011-11-30 |
| HK1113160A1 (en) | 2008-09-26 |
| US20130110408A1 (en) | 2013-05-02 |
| HK1208467A1 (en) | 2016-03-04 |
| NZ570413A (en) | 2011-07-29 |
| CA2689848A1 (en) | 2007-09-07 |
| US8304246B2 (en) | 2012-11-06 |
| WO2007098585A1 (en) | 2007-09-07 |
| JP2012255793A (ja) | 2012-12-27 |
| AU2007219666A1 (en) | 2007-09-07 |
| EP2851369A3 (de) | 2015-06-17 |
| JP5496513B2 (ja) | 2014-05-21 |
| IL193426A0 (en) | 2009-05-04 |
| EP2322531A2 (de) | 2011-05-18 |
| EP1922325A4 (de) | 2009-05-27 |
| CA2640748A1 (en) | 2007-09-07 |
| EP1922325A1 (de) | 2008-05-21 |
| KR20080104350A (ko) | 2008-12-02 |
| CA2640748C (en) | 2010-04-20 |
| EP2851369A2 (de) | 2015-03-25 |
| US20100003761A1 (en) | 2010-01-07 |
| JP2014197018A (ja) | 2014-10-16 |
| EP2322531A3 (de) | 2011-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535535T1 (de) | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen | |
| Edler et al. | Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease | |
| BRPI0516674A (pt) | método de análise de mal de alzheimer e reagente de diagnóstico | |
| DE60332538D1 (de) | Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen | |
| BRPI0112262B8 (pt) | processo para detecção e teste para um marcador de uma doença conformacional, kit, processo para identificar um composto, processo para detectar a presença de uma forma patogênica prp sc de proteína de príon, e aparelho | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| WO2005042761A3 (en) | Biomarkers for amyotrophic lateral sclerosis | |
| WO2021067850A3 (en) | METHODS OF DETECTING circRNA | |
| ATE475888T1 (de) | Biomarker zur diagnose von alzheimer | |
| DE602006015281D1 (de) | Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind | |
| DE60326153D1 (de) | Verfahren zur diagnose von morbus alzheimer | |
| SG171691A1 (en) | Biomarkers for diagnosing multiple sclerosis, and methods thereof | |
| EP2672266A3 (de) | Verfahren zum Screening einer Lungen-Transplantation Kandidat für ein erhöhtes Risiko einer Abstoßung | |
| WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
| DK1664793T3 (da) | Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser | |
| EP1600513A4 (de) | Verfahren zur untersuchung einer zelle | |
| ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
| ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
| EP2338988A4 (de) | Beurteilungs-/screeningverfahren für erkrankungen in zusammenhang mit d-aminosäure mittels dao1-/-maus | |
| ATE470152T1 (de) | Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln | |
| Klunk et al. | Small molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains | |
| BR0209681A (pt) | Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente | |
| DE60235576D1 (de) | Diagnostikum für die frühe phase von morbus alzheimer | |
| Klunk et al. | Quantitative in vitro NMR analysis of Alzheimer's, non-Alzheimer's demented and control brain | |
| ATE509270T1 (de) | Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung |